MA28882B1 - Nouveaux derives de pyrimidine et leur utilisation comme modulateurs de ppar-alpha - Google Patents

Nouveaux derives de pyrimidine et leur utilisation comme modulateurs de ppar-alpha

Info

Publication number
MA28882B1
MA28882B1 MA29787A MA29787A MA28882B1 MA 28882 B1 MA28882 B1 MA 28882B1 MA 29787 A MA29787 A MA 29787A MA 29787 A MA29787 A MA 29787A MA 28882 B1 MA28882 B1 MA 28882B1
Authority
MA
Morocco
Prior art keywords
ppar
modulators
alpha
pyrimidine derivatives
novel pyrimidine
Prior art date
Application number
MA29787A
Other languages
English (en)
Inventor
Elke Dittrich-Wengenroth
Lars Baerfacker
Axel Kretschmer
Claudia Hirth-Dietrich
Peter Ellinghaus
Martin Raabe
Hilmar Bischoff
Christian Pilger
Ulrich Rosentreter
Stephan Bartel
Klemens Lustig
Armin Kern
Dieter Lang
Marcus Bauser
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA28882B1 publication Critical patent/MA28882B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA29787A 2004-09-25 2007-03-30 Nouveaux derives de pyrimidine et leur utilisation comme modulateurs de ppar-alpha MA28882B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004046623A DE102004046623A1 (de) 2004-09-25 2004-09-25 Neue Pyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
MA28882B1 true MA28882B1 (fr) 2007-09-03

Family

ID=35063041

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29787A MA28882B1 (fr) 2004-09-25 2007-03-30 Nouveaux derives de pyrimidine et leur utilisation comme modulateurs de ppar-alpha

Country Status (22)

Country Link
US (1) US20080261990A1 (fr)
EP (1) EP1797045A1 (fr)
JP (1) JP2008514559A (fr)
KR (1) KR20070055621A (fr)
CN (1) CN101065364A (fr)
AR (1) AR051295A1 (fr)
AU (1) AU2005287589A1 (fr)
BR (1) BRPI0517327A (fr)
CA (1) CA2582492A1 (fr)
DE (1) DE102004046623A1 (fr)
EC (1) ECSP077340A (fr)
GT (1) GT200500266A (fr)
IL (1) IL182136A0 (fr)
MA (1) MA28882B1 (fr)
MX (1) MX2007003428A (fr)
NO (1) NO20072051L (fr)
PE (1) PE20060657A1 (fr)
RU (1) RU2007115215A (fr)
SV (1) SV2007002235A (fr)
TW (1) TW200628451A (fr)
UY (1) UY29127A1 (fr)
WO (1) WO2006032384A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
KR100813387B1 (ko) * 2007-06-26 2008-03-12 신명곤 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법
WO2011150286A2 (fr) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Inhibiteurs et satiogènes de recyclage d'acide biliaire pour traitement du diabète, de l'obésité et d'états inflammatoires gastro-intestinaux
WO2012030165A2 (fr) 2010-08-31 2012-03-08 서울대학교산학협력단 Utilisation de la reprogrammation fœtale d'un agoniste des ppar δ
CA2852957C (fr) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Inhibiteurs du recyclage de l'acide biliaire pour traitement de l'hypercholemie et de la maladie cholestatique hepatique
CA2853285C (fr) 2011-10-28 2020-05-05 Lumena Pharmaceuticals, Inc. Inhibiteurs du recyclage de l'acide biliaire pour traitement de maladies cholestatiques hepatiques pediatriques
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
RU2015139732A (ru) 2013-03-15 2017-04-24 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
WO2017190050A1 (fr) * 2016-04-28 2017-11-02 Cornell University Inhibiteurs de l'adénylcyclase soluble
WO2020167964A1 (fr) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Réponse dépendant du génotype et de la dose à un asbti chez des patients ayant une déficience de pompe d'exportation de sel biliaire
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU72201A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
IL182136A0 (en) 2007-07-24
TW200628451A (en) 2006-08-16
DE102004046623A1 (de) 2006-03-30
RU2007115215A (ru) 2008-11-10
AR051295A1 (es) 2007-01-03
AU2005287589A1 (en) 2006-03-30
US20080261990A1 (en) 2008-10-23
WO2006032384A1 (fr) 2006-03-30
UY29127A1 (es) 2006-04-28
NO20072051L (no) 2007-06-07
CN101065364A (zh) 2007-10-31
EP1797045A1 (fr) 2007-06-20
GT200500266A (es) 2006-05-11
KR20070055621A (ko) 2007-05-30
BRPI0517327A (pt) 2008-10-07
MX2007003428A (es) 2008-03-13
ECSP077340A (es) 2007-04-26
CA2582492A1 (fr) 2006-03-30
JP2008514559A (ja) 2008-05-08
PE20060657A1 (es) 2006-08-12
SV2007002235A (es) 2007-03-20

Similar Documents

Publication Publication Date Title
MA28882B1 (fr) Nouveaux derives de pyrimidine et leur utilisation comme modulateurs de ppar-alpha
LTPA2017004I1 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1653807T3 (da) Anvendelse af dermale mikroorganer
MA28366A1 (fr) Derives de piperidinylalkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
MA28941B1 (fr) Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MA28903B1 (fr) Derives de metastine et leur utilisation
DE602005018076D1 (de) Enantioselektive herstellung von chinolin-derivaten
MA28365A1 (fr) Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
DE602005011285D1 (de) Formmasse von polymer
MA27001A1 (fr) Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7
CR8037A (es) Derivados de 2- acilamino- 4- feniletiazol, su preparacion y su aplicacion en terapeutica
ZA200703088B (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
DK1763673T3 (da) Anvendelser af gelformuleringer
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
FR2864084B1 (fr) Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
DK1745062T3 (da) Forbedrede modulatorer af koagulationsfaktorer
MA28370A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine-carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
FR2896503B1 (fr) Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0923015A2 (pt) enxertos ósseos com atividade de protease reduzida e métodos de seleção e uso
DK1827483T3 (da) Terapeutiske formuleringer af keratinocyt-vækstfaktor
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
FR2880540B1 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2896504B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases